AstraZeneca PLC
AZNEquityAI Summary
Updated 8h ago
AstraZeneca PLC (AZN) is in a relatively unremarkable position right now
AstraZeneca PLC (AZN) is in a relatively unremarkable position right now. Momentum, flow, and extension indicators are all sitting near the middle of their historical ranges — none are signalling anything unusual. For reference: Flow Score 50/100, Trend & Momentum Score 44/100.
Market Positioning
What's Happening
AZN beat Q1 earnings expectations on April 29
AstraZeneca reported first-quarter 2026 EPS of $2.58 on April 29, topping the $1.53 consensus estimate cited by Public.com by 68.63%. The surprise matters because it signals the underlying earnings base is still running ahead of sell-side expectations, which can support valuation confidence even without a major rerating immediately following the print.
The Bigger Picture
Macro context will be updated shortly
Upcoming Catalysts
Updated 93d agoAstraZeneca’s next earnings print is the main near-term catalyst. Investors will focus on whether the company can extend the April earnings beat and confirm that 2026 EPS expectations still have room to rise.
Management commentary on product momentum, margin discipline, and capital allocation will matter as much as the reported numbers. Any shift in full-year guidance or tone on pipeline conversion could move expectations for the second half of 2026.
AstraZeneca’s prior ex-dividend date listed by HL.co.uk was 19 February 2026, so investors will be watching for the next dividend-related schedule update around the usual late-summer timing window. For income-oriented holders, the exact declaration and ex-date can help frame short-term demand for the shares.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for AstraZeneca PLC (AZN): extension is slightly below average (39th percentile), momentum is slightly above average (60th percentile), flow is slightly below average (44th percentile), volatility is below average (28th percentile).
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
AstraZeneca PLC (AZN) sits in a relatively neutral position across all four dimensions — there is no extreme reading demanding attention right now. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required